52.74
price down icon2.78%   -1.54
 
loading
Exact Sciences Corp stock is traded at $52.74, with a volume of 577.74K. It is down -2.78% in the last 24 hours and down -7.58% over the past month. Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$54.28
Open:
$54.32
24h Volume:
577.74K
Relative Volume:
0.23
Market Cap:
$10.05B
Revenue:
$2.69B
Net Income/Loss:
$-214.04M
P/E Ratio:
-45.08
EPS:
-1.17
Net Cash Flow:
$98.43M
1W Performance:
-5.85%
1M Performance:
-7.58%
6M Performance:
-5.75%
1Y Performance:
-13.69%
1-Day Range:
Value
$52.43
$54.88
1-Week Range:
Value
$52.43
$56.25
52-Week Range:
Value
$40.62
$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Name
Name
Exact Sciences Corp
Name
Phone
608-284-5700
Name
Address
5505 ENDEAVOR LANE, MADISON, WI
Name
Employee
6,600
Name
Twitter
@exactsciences
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
EXAS's Discussions on Twitter

Compare EXAS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
EXAS
Exact Sciences Corp
52.75 10.05B 2.69B -214.04M 98.43M -1.17
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
572.15 219.06B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
207.71 151.02B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
A
Agilent Technologies Inc
145.72 42.12B 6.51B 1.29B 1.37B 4.42
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
459.77 37.71B 3.84B 866.24M 792.60M 10.37
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
207.80 36.97B 15.32B 1.41B 1.96B 7.62

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-23-25 Initiated Barclays Overweight
Aug-28-24 Initiated Wells Fargo Overweight
Jun-27-24 Initiated Scotiabank Sector Outperform
Jun-03-24 Resumed Jefferies Buy
Jan-02-24 Upgrade The Benchmark Company Hold → Buy
Dec-14-23 Initiated Guggenheim Buy
Dec-13-23 Initiated Wolfe Research Outperform
Oct-10-23 Upgrade Piper Sandler Neutral → Overweight
Sep-28-23 Initiated Bernstein Outperform
Aug-02-23 Downgrade The Benchmark Company Buy → Hold
May-10-23 Upgrade Craig Hallum Hold → Buy
May-05-23 Initiated UBS Neutral
Mar-09-23 Upgrade Citigroup Neutral → Buy
Feb-10-23 Downgrade Credit Suisse Outperform → Neutral
Jan-18-23 Downgrade Raymond James Outperform → Mkt Perform
Oct-19-22 Downgrade Craig Hallum Buy → Hold
Aug-25-22 Initiated Credit Suisse Outperform
Jun-03-22 Initiated Piper Sandler Neutral
Nov-03-21 Downgrade Raymond James Strong Buy → Outperform
Jul-29-21 Reiterated BTIG Research Buy
Jul-29-21 Reiterated Canaccord Genuity Buy
Jul-29-21 Reiterated Oppenheimer Outperform
Jul-29-21 Reiterated Stifel Buy
Jun-15-21 Initiated Raymond James Strong Buy
Jun-03-21 Initiated Goldman Buy
May-25-21 Initiated Wells Fargo Equal Weight
Jan-28-21 Initiated Truist Buy
Oct-29-20 Downgrade UBS Buy → Neutral
Oct-28-20 Downgrade Citigroup Buy → Neutral
Oct-08-20 Resumed BTIG Research Buy
Apr-02-20 Initiated Evercore ISI Outperform
Jan-10-20 Resumed BTIG Research Buy
Jan-07-20 Initiated Citigroup Buy
Dec-13-19 Initiated Dougherty & Company Buy
Nov-15-19 Initiated Stifel Buy
Oct-17-19 Reiterated BofA/Merrill Buy
Oct-01-19 Resumed Craig Hallum Buy
Sep-26-19 Initiated Oppenheimer Outperform
Feb-26-19 Upgrade Goldman Neutral → Buy
Oct-09-18 Initiated UBS Buy
Sep-05-18 Resumed The Benchmark Company Hold
Aug-13-18 Reiterated Canaccord Genuity Buy
Apr-03-18 Upgrade BTIG Research Neutral → Buy
Jan-29-18 Initiated Goldman Neutral
Jan-08-18 Reiterated The Benchmark Company Buy
Nov-13-17 Downgrade Robert W. Baird Outperform → Neutral
Nov-01-17 Downgrade BTIG Research Buy → Neutral
View All

Exact Sciences Corp Stock (EXAS) Latest News

pulisher
Feb 05, 2025

Exact Sciences Co. (NASDAQ:EXAS) Receives $72.76 Average Price Target from Brokerages - MarketBeat

Feb 05, 2025
pulisher
Feb 05, 2025

Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing - BioSpace

Feb 05, 2025
pulisher
Feb 05, 2025

Jennison Associates LLC Lowers Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Feb 05, 2025
pulisher
Feb 05, 2025

Swedbank AB Boosts Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

Blue Trust Inc. Reduces Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - Defense World

Feb 04, 2025
pulisher
Feb 04, 2025

Exact Sciences Co. (NASDAQ:EXAS) Stake Boosted by Chicago Capital LLC - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Robeco Institutional Asset Management B.V. Grows Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Gagnon Securities LLC Has $13.83 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Exact Sciences' Cologuard gets FDA committee nod - WiscNews

Feb 03, 2025
pulisher
Feb 03, 2025

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call - BioSpace

Feb 03, 2025
pulisher
Feb 03, 2025

Earnings Alert: Exact Sciences Q4 2024 Results Coming February 19What Wall Street Is Watching - StockTitan

Feb 03, 2025
pulisher
Feb 02, 2025

77,053 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Baader Bank Aktiengesellschaft - MarketBeat

Feb 02, 2025
pulisher
Feb 02, 2025

Barclays Initiates Coverage of Exact Sciences (EXAS) with Overweight Recommendation - MSN

Feb 02, 2025
pulisher
Feb 02, 2025

Exact Sciences Co. (NASDAQ:EXAS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Feb 02, 2025
pulisher
Feb 01, 2025

10 Promising Biotech Stocks to Invest in (February 2025) - Securities.io

Feb 01, 2025
pulisher
Jan 31, 2025

Slow Capital Inc. Raises Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Jan 31, 2025
pulisher
Jan 27, 2025

Merit Financial Group LLC Invests $235,000 in Exact Sciences Co. (NASDAQ:EXAS) - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Exact Sciences (NASDAQ:EXAS) Research Coverage Started at Barclays - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Exact Sciences to launch Oncodetect MRD test in Q2 2025 - MSN

Jan 24, 2025
pulisher
Jan 24, 2025

Beacon Investment Advisory Services Inc. Sells 26,980 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Assenagon Asset Management S.A. Buys 12,912 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

Forecasting The Future: 19 Analyst Projections For Exact Sciences - Benzinga

Jan 23, 2025
pulisher
Jan 23, 2025

Barclays sets Exact Sciences stock price target at $70 with Overweight rating - Investing.com

Jan 23, 2025
pulisher
Jan 23, 2025

Exact Sciences Q4 EPS Estimate Reduced by Leerink Partnrs - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Exact Sciences (NASDAQ:EXAS) Now Covered by Analysts at Barclays - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Brokers Set Expectations for Exact Sciences FY2026 Earnings - MarketBeat

Jan 23, 2025
pulisher
Jan 22, 2025

Leerink Partnrs Lifts Earnings Estimates for Exact Sciences - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Exact Sciences post positive results from MRD trial - Yahoo Finance

Jan 22, 2025
pulisher
Jan 21, 2025

Exact Sciences to launch Oncodetect MRD test in Q2 2025 By Investing.com - Investing.com South Africa

Jan 21, 2025
pulisher
Jan 21, 2025

Exact Sciences (EXAS): New Evidence Validates Oncodetect's Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients - StreetInsider.com

Jan 21, 2025
pulisher
Jan 21, 2025

Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium - Business Wire

Jan 21, 2025
pulisher
Jan 21, 2025

Exact Sciences (NASDAQ:EXAS) Trading Up 5%Time to Buy? - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Exact Sciences' Oncodetect MRD Test Shows Breakthrough 91% Cancer Detection Rate in Clinical Trial - StockTitan

Jan 21, 2025
pulisher
Jan 20, 2025

Exact Sciences showcases early cancer detection test data at AACR meeting - MSN

Jan 20, 2025
pulisher
Jan 20, 2025

Avanza Fonder AB Acquires Shares of 19,512 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Jan 20, 2025
pulisher
Jan 20, 2025

Gateway Investment Advisers LLC Sells 7,902 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Jan 20, 2025
pulisher
Jan 19, 2025

5,782 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Retirement Wealth Solutions LLC - MarketBeat

Jan 19, 2025
pulisher
Jan 18, 2025

Brookstone Capital Management Decreases Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Jan 18, 2025
pulisher
Jan 17, 2025

Exact Sciences (NASDAQ:EXAS) Stock Price Down 4.3%What's Next? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Why Exact Sciences (EXAS) Is Crashing? - Insider Monkey

Jan 17, 2025
pulisher
Jan 16, 2025

Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?' - Yahoo! Voices

Jan 16, 2025
pulisher
Jan 16, 2025

Beech Hill Advisors Inc. Sells 11,383 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Jan 16, 2025
pulisher
Jan 16, 2025

2 Healthcare Stocks to Buy Hand Over Fist in January - Yahoo Finance

Jan 16, 2025
pulisher
Jan 15, 2025

Exact Sciences (NASDAQ:EXAS) Shares Gap UpStill a Buy? - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Exact Sciences (NASDAQ:EXAS) Trading Down 4.3%Here's Why - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

William Blair Reaffirms "Outperform" Rating for Exact Sciences (NASDAQ:EXAS) - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Exact Sciences Stock Surges with Strong Financials - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market - Benzinga

Jan 13, 2025
pulisher
Jan 13, 2025

Exact Sciences (NASDAQ:EXAS) Given Buy Rating at Benchmark - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Exact Sciences Boosts Finances and Plans New Launches - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Exact Sciences expects Q4 and FY revenue to beat estimates - MSN

Jan 13, 2025

Exact Sciences Corp Stock (EXAS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Exact Sciences Corp Stock (EXAS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Baranick Brian
EVP, GM, Precision Oncology
Oct 08 '24
Sale
70.00
929
65,030
12,758
$113.25
price down icon 7.95%
diagnostics_research LH
$244.81
price down icon 1.17%
$173.31
price down icon 1.13%
diagnostics_research WAT
$405.85
price down icon 0.91%
diagnostics_research MTD
$1,388.02
price up icon 2.55%
diagnostics_research IQV
$207.75
price down icon 1.18%
Cap:     |  Volume (24h):